Alnylam Pharmaceuticals, Inc. Stock

Equities

ALNY

US02043Q1076

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-04-12 EDT 5-day change 1st Jan Change
148.5 USD -2.36% Intraday chart for Alnylam Pharmaceuticals, Inc. -3.30% -22.42%
Sales 2024 * 1.85B 2.54B Sales 2025 * 2.26B 3.11B Capitalization 18.78B 25.86B
Net income 2024 * -514M -708M Net income 2025 * -243M -335M EV / Sales 2024 * 10.1 x
Net cash position 2024 * 191M 264M Net cash position 2025 * 563M 776M EV / Sales 2025 * 8.06 x
P/E ratio 2024 *
-36.2 x
P/E ratio 2025 *
-84.8 x
Employees 2,100
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.59%
More Fundamentals * Assessed data
Dynamic Chart
Sector Update: Health Care Stocks Flat to Higher Premarket Monday MT
Sector Update: Health Care MT
Alnylam Pharmaceuticals Says Phase 2 Trial for Zilebesiran Meets Primary Endpoint MT
ANALYST RECOMMENDATIONS : Chevron, Take-Two, Coinbase, Netflix, American Tower... Our Logo
Transcript : Alnylam Pharmaceuticals, Inc. - Special Call
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension CI
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Canaccord Genuity ?Genetic Medicine for Generalists?, Mar-25-2024 01:00 PM
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Stifel Virtual 2024 CNS Day, Mar-20-2024 10:00 AM
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:15 AM
Alnylam Pharmaceuticals Says Phase 2 Study of Hypertension Drug Zilebesiran Meets Primary Endpoint MT
Transcript : Alnylam Pharmaceuticals, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 09:10 AM
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran Is Added to Standard of Care Antihypertensives CI
Alnylam Pharmaceuticals Insider Sold Shares Worth $4,540,071, According to a Recent SEC Filing MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $455,357, According to a Recent SEC Filing MT
How long will this bullish phase last? Our Logo
More news

Latest transcript on Alnylam Pharmaceuticals, Inc.

1 day-2.36%
1 week-3.30%
Current month-0.64%
1 month+0.05%
3 months-23.21%
6 months-11.67%
Current year-22.42%
More quotes
1 week
148.28
Extreme 148.28
159.34
1 month
143.66
Extreme 143.66
159.34
Current year
143.52
Extreme 143.52
199.38
1 year
143.52
Extreme 143.52
218.88
3 years
117.58
Extreme 117.58
242.97
5 years
65.81
Extreme 65.81
242.97
10 years
31.38
Extreme 31.38
242.97
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 16-09-18
Director of Finance/CFO 56 19-08-12
Compliance Officer - 22-09-20
Members of the board TitleAgeSince
Director/Board Member 70 15-12-17
Director/Board Member 72 22-08-21
Director/Board Member 68 19-01-09
More insiders
Date Price Change Volume
24-04-12 148.5 -2.36% 428,052
24-04-11 152.1 -0.21% 473,419
24-04-10 152.4 -2.24% 571,403
24-04-09 155.9 -0.09% 595,961
24-04-08 156 +1.62% 738,226

Delayed Quote Nasdaq, April 12, 2024 at 04:00 pm

More quotes
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
148.5 USD
Average target price
220.2 USD
Spread / Average Target
+48.30%
Consensus